Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Tolerability of Gardasil Formulations in Preadolescents and Adolescents
NCT00092495Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2002
- Primary completion
- Sep 2004
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC) and genital warts (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Subjects Who Seroconverted for HPV 6 at Month 7, Geometric Mean Titer (GMT) for HPV 6 at Month 7 and 6 more. Started Dec 2002; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)genital warts
Beyond the preview
Go deeper on NCT00092495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092495.